静脉血栓栓塞（VTE）是实体瘤和血液恶性肿瘤的一种有据可查的并发症，但有关同种异体造血细胞移植（HCT）受者的数据较少。因此，我们在当代队列中研究了 VTE 的发生率、危险因素以及对 HCT 后结局的影响。我们回顾性审查了 2014 年 1 月至 2019 年 8 月期间接受同种异体 HCT 的患者，以确定 HCT 后发生 VTE 的患者。使用竞争风险分析来调查 VTE 的患者、疾病和移植相关风险因素。本研究总共纳入 431 名患者。移植时的中位年龄 (IQR) 为 59 岁 (46-65)。最常见的移植适应症是急性髓性白血病（49.4%）。在我们的队列中，64 名患者 (14.8%) 发生 HCT 后 VTE，中位随访时间 (IQR) 为 24.6 (8.4-47.1) 个月。 VTE的累积发生率为6个月时4.2%、12个月时9.0%、24个月时12.6%和36个月时13.8%。在多变量分析中，年龄较大（HR 每 10 年增加，95% CI：1.36，1.09-1.70）VTE 病史（HR，95% CI：1.95，1.09-3.49）和 2-4 级急性 GVHD（HR） , 95% CI: 1.75, 1.05-2.94) 与 VTE 独立相关。 VTE 与非复发死亡率 (NRM) 风险增加（HR4.09，95% CI 2.47-6.74）和总生存期（OS）降低（HR 2.19，95% CI 1.48-3.24）显着相关。 VTE 是同种异体 HCT 后的一个重要并发症，与 NRM 增加和 OS 降低显着相关。老年患者、既往患有 VTE 的患者以及患有急性 GVHD 的患者在 HCT.Thieme 后发生 VTE 的风险增加。版权所有。

Venous thromboembolism (VTE) is a well-documented complication of both solid and hematologic malignancies, but there are fewer data on allogeneic hematopoietic cell transplant (HCT) recipients. Therefore, we studied the incidence, risk factors, and impact of VTE on post-HCT outcomes in a contemporary cohort. We retrospectively reviewed patients who underwent allogeneic HCT between 1/2014 and 8/2019 to identify patients with post-HCT VTE. Patient, disease, and transplant-related risk factors for VTE were investigated using competing risk analysis. A total of 431 patients were included in this study. Median (IQR) age in years was 59 (46-65) at transplant. The most common indication for transplant was acute myelogenous leukemia (49.4%). Within our cohort, 64 patients (14.8%) developed post-HCT VTE with a median (IQR) follow up time of 24.6 (8.4- 47.1) months. The cumulative incidence of VTE was 4.2% at 6-month, 9.0% at 12-month, 12.6% at 24-month and 13.8% at 36-months. In multivariable analysis, older age (HR per 10-year increase, 95% CI: 1.36, 1.09-1.70) history of VTE (HR, 95% CI : 1.95, 1.09-3.49), and grade 2-4 acute GVHD (HR, 95% CI: 1.75, 1.05-2.94) were independently associated with VTE. VTE was significantly associated with an increased risk of non-relapse mortality (NRM) (HR4.09, 95% CI 2.47-6.74) and decreased overall survival (OS) (HR 2.19, 95% CI 1.48-3.24). VTE is an important complication after allogeneic HCT and is significantly associated with increased NRM and decreased OS. Older patients, those with prior VTE, and patients with acute GVHD are at increased risk for development of VTE after HCT.Thieme. All rights reserved.